Medulloblastoma in childhood: Revisiting Intrathecal therapy in infants and children

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1173-1189

  Conroy, Sharon ^a   Garnett, Martin ^a   Vloeberghs, Michael ^a   Grundy, Richard ^a   Craven, Ian ^a   Walker, David ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Child; Cns drug delivery; Intrathecal chemotherapy; Leptomeningeal metastasis; Medulloblastoma

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYTARABINE; DACARBAZINE; DIAZIQUONE; DIDEMNIN B; EFLORNITHINE; ETOPOSIDE; FAZARABINE; FLOXURIDINE; GEMCITABINE; IRINOTECAN; LOMUSTINE; LONIDAMINE; MAFOSFAMIDE; MENOGARIL; MERCAPTOPURINE; MITOLACTOL; NIMUSTINE; RANIMUSTINE; RUBITECAN; SPARTAJECT; TAUROMUSTINE; TEMOZOLOMIDE; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINOSTATIN; ANTINEOPLASTIC AGENT;

ACUTE BRAIN DISEASE; ARACHNOIDITIS; ARTICLE; ASTROCYTOMA; BRAIN EDEMA; BRAIN METASTASIS; BRAIN STEM TUMOR; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CHILD; CHILD HEALTH; CHILDHOOD CANCER; CLINICAL TRIAL; COMA; CONFUSION; CONTINUOUS INFUSION; CONVULSION; CRANIOPHARYNGIOMA; DROWSINESS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INFORMATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EPENDYMOBLASTOMA; EPENDYMOMA; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; INCONTINENCE; INFANT; INTRACAVITARY DRUG ADMINISTRATION; LEUKEMIA; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MELANOMA; MENINGIOMA; MULTIPLE MYELOMA; NECROSIS; NEUROBLASTOMA; NEUROECTODERM TUMOR; NEUROTOXICITY; NONHUMAN; PARAPLEGIA; PHYSICAL CHEMISTRY; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; RETINOPATHY; SEIZURE; SIDE EFFECT; SOLID TUMOR; SUSTAINED RELEASE PREPARATION; VASCULAR NECROSIS; WEAKNESS; CEREBELLUM TUMOR; INTRASPINAL DRUG ADMINISTRATION; PRESCHOOL CHILD; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; INJECTIONS, SPINAL; MEDULLOBLASTOMA; TREATMENT OUTCOME;

EID: 77951904474     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1127-1     Document Type: Article

References (151)

1. Interactive analysis LogP and LogW Predictors. http://www.logp.com
2. Aaron R, Elion G, Colvin O, Graham M, Keir S, Bigner D, Friedman H (1994) Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 35:127-131
3. Allinson R, Stach P (1978) Intrathecal drug therapy. Drug Intell Clin Pharmacy 12:347-359
4. Archer G, Sampson J, McLendon R, Friedman A, Colvin O, Rose M, Sands H, McCullough W, Fuchs H, Bigner D, Friedman H (1999) Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J Neurooncol 44:233-241
5. Arita N, Ushio Y, Hayakawa T, Nagatani M, Huang T-Y, Izumoto S, Mogami H (1988) Intrathecal ACNU-a new therapeutic approach against malignant leptomeningeal tumors. J Neurooncol 6:221-226
6. Arndt C, Colvin O, Balis F, Lester C, Johnson G, Poplack D (1987) Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys. Cancer Res 47:5932-5934
7. Ashley D, Merchant T, Zhou T, Coleman L, Pollack I, Duffner P, Burger P, Miller D, Buxton A, Douglas S (2008) Systemic chemotherapy, second-look surgery and conformal radiation therapy limited to the posterior fossa and primary site for children >8 months and <3 years with non-metastatic medulloblastoma: a Children's Oncology Group phase III study. Neurooncology 10:436-437
8. Association of the British Pharmaceutical Industry (1999) ABPI Compendium of data sheets and summaries of product characteristics 1999-2000. Datapharm Publications, London
9. Baker S, Heideman RL, Crom WR, Kuttesch J, Gajjar A, Stewart C (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion Topotecan in children with central nervous system tumours. Cancer Chemother Pharmacol 37:195-202
10. Bates S, Raphaelson M, Price R, McKeever P, Cohen S, Poplack D (1985) Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: correlation with cerebrospinal fluid myelin basic protein. Med Pediatr Oncol 13:4-8
11. Bayer (1999) Information from medical information department. Newbury, Berkshire
12. Bender J, Grillo-Lopez A, Posada Jnr J (1983) Diaziquone (AZQ). Investig New Drugs 1:71-84
13. Berg S, Balis F, Zimm S, Murphy R, Holcenberg J, Sato J, Reaman G, Steinherz P, Gillespie A, Doherty K, Poplack D (1992) Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 10:143-148
14. Bernardi R, Bomgaars L, Fox E, Balism F, Egorin M, Lagattuta T, Aikin A, Whitcome P, Renbarger J, Lieberman F, Berg S, Blaney S (2008) Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol 62:355-361
15. Bhojwani D, Pui C-H (2008) Intrathecal liposomal cytarabine: more friend than foe? Leuk Lymphoma 49:1427-1430
16. Blaney S, Boyett J, Friedman H, Gajjar A, Geyer R, Horowitz M, Hunt D, Kieran M, Kun L, Packer R, Phillips P, Pollack M, Prados M, Heideman R (2005) Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: A Pediatric Brain Tumor Consortium study (PBTC-001). J Clin Oncol 23:525-531
17. Blaney S, Cole D, Godwin K, Sung C, Poplack D, Balis F (1995) Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 36:121-124
18. Blaney S, Heideman R, Berg S, Adamson P, Gillespie A, Geyer J, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack D, Ballis F (2003) Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21:143-147
19. Blaney S, Poplack D (1996) Pharmacologic strategies for the treatment of meningeal malignancy. Investig New Drugs 14:69-85
20. Blaney S, Poplack D (1998) New cytotoxic drugs for intrathecal administration. J Neurooncol 38:219-223
21. Bleyer W (1999) Intrathecal depot cytarabine therapy: a welcome addition to a limited armametarium. Clin Cancer Res 5:3349-3351
22. Bleyer W, Coccia P, Sather H et al (1983) Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1:317-325
23. Bleyer W, Drake J, Chabner B (1973) Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289:770-773
24. Boiardi A, Eoli M, Pozzi A, Salmaggi A, Broggi G, Silvani A (1999) Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Ital J Neurol Sci 20:43-48
25. Boland I, Vassal G, Morizet J, Terrier-Lacombe M-J, Valteau-Couanet D, Kalifa C, Hartmann O, Gouyette A (1999) Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 79:787-792
26. Bomgaars L, Geyer J, Franklin J, Dahl G, Park J, Winick N, Klenke R, Berg S, Blaney S (2004) Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 19:3916-3921
27. Brandes A, Pasetto L, Monfardini S (2000) New drugs in recurrent high grade gliomas. Anti-Cancer Res 20:1913-1920
28. Brem H, Piantadosi S, Burger P, Walker M, Selker R, Vick N, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold S (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012
29. British Medical Association & Royal Pharmaceutical Society of Great Britain (2000) British National Formulary. BMA & RPS (GB), London
30. Castleberry R, Ragab A, Steuber C, Kamen B, Toledano S, Starling K, Norris D, Burger P, Krischer J (1990) Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. Investig New Drugs 8:401-406
31. Chamberlain M, Khatibi S, Kim J, Howell S, Chatelut E, Kim S (1993) Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC101). Arch Neurol 50:261-264
32. Chamberlain M, Kormanik P, Howell S, Kim S (1995) Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52:912-917
33. Champagne M, Silver H (1992) Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma. J Natl Cancer Inst 84:1203-1204
34. Chen Y-M, Chen M-C, Tsai C-M, Perng R-P (2003) Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis-a case report. Lung Cancer 40:99-101
35. Crawford S, Rustin G, Bagshawe K (1986) Acute neurological toxicity of intrathecal cytosine arabinoside. Cancer Chemother Pharmacol 16:306-307
36. Damon L, Plunkett W, Linker C (1991) Plasma and cerebrospinal fluid pharmacokinetics of 1-β-D-arabinofuranosylcytosine and 1-β-D- arabinofuranosyluracil following the repeated intravenous administration of high-and intermediate-dose β-D-arabinofuranosylcytosine. Cancer Res 51:4141-4145
37. Department of Health (2008) Updated national guidance on the safe administration of intrathecal chemotherapy. In: Health Do (ed) Dodion P, Sanders C, Georges P, Kenis Y (1988) In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 22:80-82
38. Dollery C (ed) (1999) Therapeutic drugs. Churchill Livingstone, Edinburgh
39. Doz F, Pinkerton R (1994) What is the place of carboplatin in paediatric oncology? Eur J Cancer 30A: 194-201
40. Drayton C (ed) (1990) Comprehensive medicinal chemistry. Pergamon Press, Oxford
41. Eagan R, Dinapoli R, Cascino T, Scheithauer B, O'Neill B, O'Fallon R (1987) Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors. J Neurooncol 5:309-314
42. Edwards M, Levin V, Seager M, Wilson C (1981) Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma. Child's Brain 8:444-451
43. Egorin M, Zuhowski E, McCully C, Blaney S, Kerr J, Berg S, Ballis F (2002) Pharmacokinetics of intrathecal gemcitabine in non-human primates. Clin Cancer Res 8:2437-2442
44. Englehard H (2000) The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 53:458-464
45. Ettinger L, Ru N, Krailo M, Ruccione K, Krivit W, Hammond G (1990) A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: a report from the Children's Cancer Study Group. J Neurooncol 9:69-76
46. Ewend M, Sampath P, Williams J, Tyler B, Brem H (1998) Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 43:1185-1193 (Pubitemid 128723309)
47. Fleischhack G, Jaehde U, Bode U (2005) Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 4:1-31
48. Friedman H (2000) Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol 27:35-40
49. Friedman H, Bigner S, Bigner D (1995) Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). J Neurooncol 24:103-108
50. Friedman H, Ochs J, Finlay J, Geyer R, Arndt C, Cohen B, Phillips P, Strauss L, Hochberg F, Schold S, Bigner D, Colvin O (1993) Phase I trial of intrathecal 4-hydroperoxycyclophosphamide for neoplastic meningitis. American Association for Cancer Research. p 269
51. Green L (1988) Choice of diluents for intrathecal drug administration. Clin Pharmacy 7:265-266
52. Grill J, Sainte-Rose C, Jouvet A, Gentet J-C, Lejars O, Frappaz D, Doz F, Rialland X, Pichon F, Bertozzi A-I, Chastagner P, Couanet D, Habrand J-L, Raquin M-A, Le Deley M-C, Kalifa C (2005) Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6:573-580
53. 111Indium DTPA ventriculography. Am J Med 73:641-647
54. Gururangan S, Petros W, Young Poussaint T, Hancock M, Phillips P, Friedman H, Bomgaars L, Blaney S, Kun L, Boyett J (2006) Phase I trial of intrathecal Spartaject Busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study (PBTC-004). Clin Cancer Res 12:1540-1546
55. Gutman R, Peacock G, Lu D (2000) Targeted drug delivery for brain cancer treatment. J Controlled Release 65:31-41
56. Haberler C, Varlet P, Legoix P, Fattet S, Janoueix-Lerosey I, Lellouch-Tubiana A, Grill J, Doz F, Sainte-Rose C, Delattre O (2008) Widespread nuclear beta-catenin expression in medulloblastoma correlates with mutation status of CTNNB1 gene encoding beta-catenin. Neurooncology 10:470
57. Hare C, Elion G, Houghton P, Houghton J, Keir S, Marcelli S, Bigner D, Friedman H (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39:187-191
58. Heideman RL, McCully C, Balis F, Poplack D (1993) Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. Investig New Drugs 11:135-140
59. Hori T, Tanaka S, Nishiyama M, Kamitani H, Watanabe T, Tabuchi F, Tatsuhara T, Nakajima E (1993) Distribution of intrathecally administered ACNU in mongrel dogs: pharmacokinetics and quantitative autoradiographic study. Surg Neurol 40:183-195
60. Houchens D, Ovejera A, Riblet S, Slagel D (1983) Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 19:799-805
61. Huang T-Y, Howng S-L (1997) Intrathecal ACNU against experimental leptomeningeal tumors. Kaohsiung J Med Sci 13:626-630
62. Hussain M, Wozniak A, Edelstein M (1993) Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 14:61-75
63. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214-3218
64. Jaeckle K, Batchelor T, O'Day S, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil J, Baidas S, Kennedy J, Mason W, Moots P, Russell C, Swinnen L, Howell S (2002) An open label trial of sustainedrelease cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57:231-239
65. Kerr J, Berg S, Dauser R, Nuchtern J, Egorin M, McGuffey L, Aleksic A, Blaney S (2001) Plasma and cerebrospinal fluid pharmacokinetics. Cancer Chemother Pharmacol 47:411-414
66. Kim S, Chatelut E, Kim J, Howell S, Cates C, Kormanik P, Chamberlain M (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11:2186-2193
67. Kim S, Khatibi S, Howell S, McCully C, Balis F, Poplack D (1993) Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 53:1596-1598
68. Kim S, Kim D, Geyer M, Howell S (1987) Multivesicular liposomes containing 1-β-D-arabinofuranosylcytosine for slowrelease intrathecal therapy. Cancer Res 47:3935-3937
69. Kimler B, Liu C, Evans R, Morantz R (1992) Intracerebral chemotherapy in the 9L rat brain tumor model. J Neurooncol 14:191-200
70. Kitamura I, Kochi M, Matsumoto Y, Ueoka R, Kuratsu J-I, Ushio Y (1996) Intrathecal chemotherapy with 1, 3-bis (2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study. Cancer Res 56:3986-3992
71. Kleinschmidt-De Masters B, Yeh M (1992) "Locked-in syndrome" after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 70:2504-2507
72. Kochi M, Kuratsu J-I, Mihara Y, Takaki S, Inoue N, Sueyoshi N, Uemura S, Ushio Y (1990) Neurotoxicity and pharmacokinetics of intrathecal perfusion of ACNU in dogs. Cancer Res 50:3119-3123
73. Kochi M, Kuratsu J-I, Mihara Y, Takaki S, Seto H, Uemura S, Ushio Y (1993) Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(chloroethyl)-1-nitrosourea hydrochloride. Neurosurgery 33:817-823
74. Kochi M, Takaki S, Kuratsu J-I, Seto H, Kitamura I, Ushio Y (1994) Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-gluco-pyranoside (MCNU) in dogs. J Neurooncol 19:239-244
75. ™ drug delivery matrix after intrathecal administration of sustained-release encapsulated cytarabine in rats. Drug Deliv 5:143-151
76. Kooistra K, Rodriguez M, Powis G (1989) Toxicity of intrathecally administered cytotoxic drugs and their antitumor activity against an intrathecal Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat. Cancer Res 49:977-982
77. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81
78. Kuhl J, Doz F, Taylor R (2004) Embryonic tumors. In: Walker D, Perilongo G, Punt J, Taylor R (eds) Brain and spinal tumors of childhood. Arnold, London, pp 314-330
79. Lassaletta A, Lopez-Ibor B, Mateos E, Gonzalez-Vicent M, Perez-Martinez A, Sevilla J, Diaz M, Madero L (2009) Intrathecal liposomal cytarabine in children under 4 years with malignant brian tumours. J Neurooncology (in press)
80. Levin V, Byrd D, Sikic B, Etiz B, Campbell J, Borcich J, Davis R (1985) Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. Cancer Res 45:3810-3815
81. Levin V, Chamberlain M, Silver P, Rodriguez L, Prados M (1989) Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 23:301-307
82. Levin V, Edwards M, Gutin P, Vestnys P, Fulton D, Seager M, Wilson C (1984) Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma and malignant astrocytoma. J Neurosurg 61:1063-1068
83. Lind M (1993) Pharmacokinetics of alkylating agents. Pharmacokinet Cancer Chemother 17:157-179
84. MacDonald D (1991) Neurologic complications of chemotherapy. Neurol Clin 9:955-967
85. Martindale (1999) The complete drug reference. Pharmaceutical Press, London
86. McKeran R, Firth G, Oliver S, Uttley D, O'Laoire S (1985) A potential application for the intracerebral injection of drugs entrapped within liposomes in the treatment of human cerebral gliomas. J Neurol Neurosurg Psychiatry 48:1213-1219
87. McVie J (1992) Teniposide (VM-26) in brain tumors. Semin Oncol 19:85-88
88. Morantz R, Kimler B, Vats T, Henderson S (1983) Leomycin and brain tumors. J Neurooncol 1:249-255
89. Nakagawa H, Maeda N, Tsuzuki T, Suzuki T, Hirayama A, Miyahara E, Wada K (2001) Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors. Jpn J Clin Oncol 31:251-258
90. Nakagawa H, Miyahara E, Suzuki T, Wada K, Tamura M, Fukushima Y (2005) Continuous intrathecal administration of 5-fluoro-2'-deoxyuridine for the treatment of neoplastic meningitis. Neurosurgery 57:266-280
91. Nakagawa H, Yamada M, Fukushima M, Ikenaka K (1999) Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. Cancer Chemother Pharmacol 43:247-256
92. Nakagawa H, Yamada M, Maeda N, Iwatsuki K, Hirayama Z, Ikenaka K (1999) Clinical trial of intrathecal administration of 5-fluoro-2'-deoxyuridine for treatment of meningeal dissemination of malignant brain tumors. J Neurooncol 45:175-183
93. National Cancer Institute. http://www.nci.nih.gov
94. National Library of Medicine Special Information Services. http://chem.sis.nlm.nih.gov
95. Newlands E, Stevens M, Wedge S, Wheelhouse R, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61
96. Nishio S, Morioka T, Takeshita I, Tadahisa S, Takanori I, Fujiwara S, Fukui M (1995) Chemotherapy for progressive pilocytic astrocytomas in the chiasmo-hypothalamic regions. Clin Neurol Neurosurg 87:300-306
97. Ochiai H, Pernell C, Archer G, Chewning T, McLendon R, Friedman H, Sampson J (2006) Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. Neurol Med Chir (Tokyo) 46:485-490
98. Olivi A, Dundan L, Corden B, Lenartz D, Brem H (1993) Direct delivery of platinum based neoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemotherapy Pharmacol 31:449-454
99. Paal C, Erdelyi-Toth V, Pap E, Csaki C, Ferencz T, Schuler D, Borsi J (1994) Pharmacokinetic studies on Elobromol in children with brain tumors. Anti-Cancer Drugs 5:539-547
100. Pardridge W (1996) Brain drug delivery and blood-brain barrier transport. Drug Deliv 3:99-115
101. Pardridge W (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139
102. Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 14(5):189-194
103. Phillips P, Than T, Cork L, Hilton J, Carson B, Colvin O, Grochow L (1992) Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Cancer Res 52:6168-6174
104. Read T-A, Thorsen F, Bjerkvig R (2002) Localised delivery of therapeutic agents to CNS malignancies; old and new approaches. Curr Pharm Technol 3:257-273
105. Rhone Poulenc Rorer (1999) Information from medical information department. West Malling, Kent
106. Riccardi R, Riccardi A, Di Rocco C, Carelli G, Tartaglia R, Lasorella A, Servidei T, Mastrangelo R (1992) Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors. Cancer Chemother Pharmacol 30:21-24
107. Ruggiero A, Conter V, Milani M, Biagi E, Lazzareschi I, Sparano P, Riccardi R (2001) Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs 3:237-246
108. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, Graf N, Emser A, Pietsch T, Wolff J, Korkmann R, Kuehl J (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978-986
109. Rutkowski S, Von Hoff K, Emser A, Garre ML, Walker D, Grundy R, Dhall G, Finlay J, Grill J (2008) Prognostic factors and survival of young children with medulloblastoma: an international meta-analysis. Neurooncology 10:437
110. Sampson J, Archer G, Villavicencio A, McLendon R, Friedman A, Bishop W, Bigner D, Friedman H (1999) Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 5:1183-1188
111. Savaraj N, Feun L, Lu K, Gray K, Wang C, Loo T (1992) Pharmacology of intrathecal VP-16-213 in dogs. J Neurooncol 13:211-215
112. Savas A, Erdem A, Tun K, Kanpolat Y (2000) Fatal toxic effect of bleomycin in brain tissue after intracystic chemotherapy for a craniopharyngioma: case report. Neurosurgery 46:213-217
113. Schmandt S, Kuhl J (1998) Chemotherapy as prophylaxis and treatment of meningosis in children less than 3 years of age with medulloblastoma. J Neurooncol 38:187-192
114. Schold S Jr, Mahaley M Jr, Vick N, Friedman H, Burger P, De Long E, Albright R Jr, Bullard D, Khandekar D, Cairncross J, Macdonald D, Falletta J (1987) Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. J Clin Oncol 5:464-471
115. Schuler D, Somlo P, Borsi J, Paraicz E, Revesz T, Kardos G, Koos R (1988) New drug combination for the treatment of relapsed brain tumors in children. Pediatr Hematol Oncol 5:153-156
116. Schuler D, Somlo P, Koos R, Kalmanchey R, Paraicz E (1992) Treatment of malignant scala posterior brain tumors in children: the chemotherapy of relapsed medulloblastoma with a dibromdulcitol-containing drug regime and pharmacokinetic studies of dibromdulcitol in children. Med Pediatr Oncol 20:312-314
117. Screnci D, McKeage M, Galettis P, Hambley T, Palmer B, Baguley B (2000) Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82:966-972
118. Selby G, Upchurch C, Townsend J, Eyre H (1994) A phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study. Cancer Chemother Pharmacol 34:179-180
119. Slavc I, Schuller E, Czech T, Hainfellner J, Seidl R, Dieckmann K (1998) Intrathecal mafosfamide therapy for paediatric brain tumors with meningeal dissemination. J Neurooncol 38:213-218
120. Slavc I, Schuller E, Falger J, Gunes M, Pillwein K, Czech T, Dietrich W, Rossler K, Dieckmann K, Prayer D, Hainfellner J (2003) Feasibility of long-tem intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11) : experience in 26 children with disseminated malignant brain tumors. J Neurooncol 64:239-247
121. SmithKline Beecham Pharmaceuticals (1999) Information from medical information department. Welwyn Garden City
122. Stempien L, Tsai T (2000) Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 79:536-541
123. Stevens M, Newlands E (1993) From triazines and triazines to temozolomide. Eur J Cancer 29a: 1045-1047
124. Stiller C, Bleyer W (2004) Epidemiology. In: Walker D, Perilongo G, Punt J, Taylor R (eds) Brain and spinal tumors of childhood. Arnold, London, pp 35-49
125. Taylor E (2002) The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 41:81-92
126. Taylor S (1994) New agents in the treatment of primary brain tumors. J Neurooncol 20:141-153
127. Tomlinson F, Lihou M, Smith P (1991) Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas. Br J Cancer 64:1051-1059
128. Tsuboi K, Yoshii Y, Hyodo A, Takada K, Nose T (1995) Leukoencephalopathy associated with intra-arterial ACNU in patients with gliomas. J Neurooncol 23:223-231
129. Tuxen M, Hansen S (1994) Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20:191-214
130. Ushio Y, Kochi M (1998) Intrathecal perfusion chemotherapy with ACNU against subarachnoid dissemination of glioma in children. Int J Pediat Hem Oncol 5:55-56
131. Ushio Y, Kochi M, Kitamura I, Kuratsu J (1998) Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)-methyl]-1-(2-cloroethyl)-1-nitrosourea hydrochloride for subarachnoid dissemination of gliomas. J Neurooncol 38:207-212
132. van der Gaast A, Sonneveld P, Mans D, Splinter T (1992) Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol 29:335-337
133. van der Graaf W, Haaxma-Reiche H, Burghouts J, Postmus P (1993) Teniposide for meningeal carcinomatosis of small cell lung cancer. Lung Cancer 10:247-249 (Pubitemid 24033210)
134. Vassal G, Boland I, Santos A, Bissery M, Terrier-Lacombe M, Morizet J, Sainte-Rose C, Lellouch-Tubiana A, Kalifa C, Gouyette A (1997) Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 73:156-163
135. 6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin Cancer Res 4:463-468
136. Vassal G, Pondarre C, Boland I, Cappelli C, Santos A, Thomas C, Lucchi E, Imadalou K, Pein F, Morizet J, Gouyette A (1998) Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 80:271-280
137. Vassal G, Terrier-Lacombe M-J, Bissery M, Venuat A, Gyergyay F, Benard J, Morizet J, Boland I, Ardouin P, Bressacde-Paillerets B, Gouyette A (1996) Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 75:537-545
138. Walker D, Wilne S (2005) Treatment of medulloblastoma in young children. Lancet Oncol 6:541-542
139. Wang P, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Deliv 54:987-1013
140. Ward H (1978) Central nervous system tumors of childhood treated with CCNU, vincristine and radiation. Med Pediatr Oncol 4:315-320
141. Watterson J, Toogood I, Nieder M, Morse M, Frierdich S, Lee Y, Moertel C, Priest J (1994) Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 74:3034-3041
142. Weiss R, Issell B (1982) The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 9:313-330
143. ® wafer in initial surgery for malignant glioma: longterm follow-up of a multicenter controlled trial. Acta Neurochir 148:269-275
144. Yamada M, Nakagawa H, Fukushima M, Shimizu K, Hayakawa T, Ikenaka K (1998) In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. J Neurooncol. 37:115-121 (Pubitemid 28073583)
145. Yamasaki T, Kikuchi H, Yamashita J, Asato R, Fujita M (1989) Primary spinal intramedullary malignant melanoma: case report. Neurosurgery 25:117-121
146. Yamashima T, Yamashita J, Shoin K (1990) Neurotoxicity of local administration of two nitrosoureas in malignant gliomas. Neurosurgery 26:794-800
147. Yoshida T, Beuls E, Shimizu K, Koulousakis A, Sturm V (1992) Intrathecal chemotherapy with ACNU for meningeal gliomatosis. Br J Cancer 66:999-1004
148. Yoshida T, Shimizu K, Koulousakis A, Sturm V (1992) Intrathecal chemotherapy with ACNU in a meningeal gliomatosis rat model. J Neurosurg 77:778-782
149. Yoshimura J, Nishiyama K, Mori H, Takahashi H, Fujii Y (2008) Intrathecal chemotherapy for refractory disseminated medulloblastoma. Child's Nerv Syst 24:581-585
150. Zimm S, Collins J, Curt G, O'Neill D, Poplack D (1984) Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res 44:1698-1701 (Pubitemid 14125867)
151. Zimm S, Collins J, Miser J, Chatterji D, Poplack D (1984) Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Therap 35:826-830